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Abstract
Background: With concerns about the disastrous health and economic consequences caused by the influenza
pandemic, comprehensively understanding the global host response to influenza virus infection is urgent. The role
of microRNA (miRNA) has recently been highlighted in pathogen-host interactions. However, the precise role of
miRNAs in the pathogenesis of influenza virus infection in humans, especially in critically ill patients is still unclear.
Methods: We identified cellular miRNAs involved in the host response to influenza virus infection by performing
comprehensive miRNA profiling in peripheral blood mononuclear cells (PBMCs) from critically ill patients with
swine-origin influenza pandemic H1N1 (2009) virus infection via miRNA microarray and quantitative reverse-
transcription polymerase chain reaction (qRT-PCR) assays. Receiver operator characteristic (ROC) curve analysis was
conducted and area under the ROC curve (AUC) was calculated to evaluate the diagnostic accuracy of severe H1N1
influenza virus infection. Furthermore, an integrative network of miRNA-mediated host-influenza virus protein
interactions was constructed by integrating the predicted and validated miRNA-gene interaction data with
influenza virus and host-protein-protein interaction information using Cytoscape software. Moreover, several hub
genes in the network were selected and validated by qRT-PCR.
(Continued on next page)
* Correspondence: zhangdeli@tsinghua.org.cn; jun.cheng.ditan@gmail.com
†Equal contributors
1MOA Key Laboratory of Animal Biotechnology of National Ministry of
Agriculture, Institute of Veterinary Immunology, and Research Laboratory of
Virology, Immunology & Bioinformatics, Division of Veterinary Microbiology &
Virology, Department of Preventive Veterinary Medicine, College of
Veterinary Medicine, Northwest A & F University, Yangling, 712100, Xi’an City,
Shaanxi Province, China
2Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical
University, Beijing 100015, China
Full list of author information is available at the end of the article
© 2013 Song et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Song et al. BMC Infectious Diseases 2013, 13:257
http://www.biomedcentral.com/1471-2334/13/257
(Continued from previous page)
Results: Forty-one significantly differentially expressed miRNAs were found by miRNA microarray; nine were
selected and validated by qRT-PCR. QRT-PCR assay and ROC curve analyses revealed that miR-31, miR-29a and miR-
148a all had significant potential diagnostic value for critically ill patients infected with H1N1 influenza virus, which
yielded AUC of 0.9510, 0.8951 and 0.8811, respectively. We subsequently constructed an integrative network of
miRNA-mediated host-influenza virus protein interactions, wherein we found that miRNAs are involved in regulating
important pathways, such as mitogen-activated protein kinase signaling pathway, epidermal growth factor receptor
signaling pathway, and Toll-like receptor signaling pathway, during influenza virus infection. Some of differentially
expressed miRNAs via in silico analysis targeted mRNAs of several key genes in these pathways. The mRNA
expression level of tumor protein T53 and transforming growth factor beta receptor 1 were found significantly
reduced in critically ill patients, whereas the expression of Janus kinase 2, caspase 3 apoptosis-related cysteine
peptidase, interleukin 10, and myxovirus resistance 1 were extremely increased in critically ill patients.
Conclusions: Our data suggest that the dysregulation of miRNAs in the PBMCs of H1N1 critically ill patients can
regulate a number of key genes in the major signaling pathways associated with influenza virus infection. These
differentially expressed miRNAs could be potential therapeutic targets or biomarkers for severe influenza virus
infection.
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Background
In 2009, human infection with novel swine-origin influ-
enza A (H1N1) virus became a health burden through-
out the world. The H1N1 virus spread rapidly to
countries worldwide, leading the World Health
Organization (WHO) to declare on 11 June 2009 the
first influenza pandemic in more than 40 years [1].
Like other viruses, influenza virus relies on host cellu-
lar processes throughout its replication cycle. Various
strategies have been used to characterize host factors in-
volved in influenza virus infection to better understand
the molecular mechanisms of viral pathogenesis. These
strategies include yeast two-hybrid analysis [2], genome-
wide RNA interference (RNAi) screen [3-5], and integra-
tive analysis combining several different approaches
[6,7]. Hundreds of host proteins have been identified
and a physical, regulatory, and functional map of host-
influenza interactions has been drawn, which shows the
global perspective of virus infection and uncovers the
complex host-pathogen relationships. However, the con-
crete mechanism is still unclear; more studies relevant
to influenza virus are still needed.
MicroRNAs (miRNAs) are small (~22 nucleotides
long), single-stranded non-coding RNAs that mediate
posttranscriptional silencing of target genes. In animals,
miRNAs usually bind to complementary sites in the 3′
untranslated region (UTR) of specific target genes,
resulting in inhibited protein expression and induced
target mRNA degradation [8]. MiRNAs have emerged as
key regulators of diverse biological processes, including
development [9], cancer [10], immune response [8,11]
and so on. Special miRNAs have been reported to par-
ticipate in regulating cross-talk between the host and the
pathogen in viral infections and have a major function in
viral pathogenesis [12-14]. For influenza virus, differen-
tial expression of cellular miRNAs have been found both
in avian influenza virus-infected chickens [15,16] and
reconstructed 1918 influenza virus [17] or the highly
pathogenic avian influenza H5N1 virus [18] infected
mice. Several cellular miRNAs, such as miR-323, miR-
491, miR-654, and Let-7c have recently been reported to
inhibit H1N1 influenza A virus replication by
downregulating the viral gene expression in infected
MDCK or A549 cells [19,20]. In addition, temporal- and
strain-specific host miRNA molecular signatures have
been demonstrated in human A549 cells infected with
swine-origin influenza pandemic H1N1 (2009) and
highly pathogenic avian-origin influenza H7N7 (2003)
[21]. However, it is still unclear whether miRNAs also
play an important role in human being infected with in-
fluenza virus, especially critically ill patients caused by
influenza virus infection.
Human peripheral blood mononuclear cells (PBMCs)
provide an important source for clinical diagnosis and
pathogenesis discovery. In contrast to target tissue bi-
opsy, blood is not limited by restricted access to target
tissues. Blood is a highly dynamic environment, which is
another advantage. Blood has been proposed as a ‘senti-
nel tissue’ that reflects disease progression in the body
[22]. The leukocytes can interact and communicate with
practically every tissue so that these cells have rich infor-
mation regarding inflammation and immune responses.
Gene expression profiling in peripheral blood has been
used to describe the pathogenesis of infectious diseases,
including influenza, and to discover unique signatures of
disease or to identify novel drug targets for treatment
[22-33]. Influenza A virus can infect and replicate in hu-
man primary dendritic cell (DC), macrophages, and
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natural killer cells [34-36]. Therefore, it is appropriate to
use PBMC for gene expression profiling, and it holds
great promise for clinical diagnosis and research [22].
Although multiple signaling pathways and various cel-
lular factors have been associated with influenza virus
infection, the function of the miRNAs of PBMCs is still
poorly understood. In the current study, we used
both miRNA microarray and quantitative reverse-
transcription polymerase chain reactions (qRT-PCR)-
based approaches to assess miRNA expression in
PBMCs from the critically ill patients with H1N1 infec-
tion, and found some differentially expressed miRNAs
that can be highly related to influenza virus infection.
We subsequently constructed a direct gene interaction
network to illustrate the interaction mechanism of these
miRNA targets with each other via protein-protein inter-
action during influenza virus infection. This network re-
vealed potential important functions that miRNAs have
in host and pathogen interactions, and provided several
directions for further study. We then validated several
hub genes in the network using the qRT-PCR method
and demonstrated that the hub genes, which are highly
important during influenza virus infection, can be mod-
ulated by multiple miRNAs.
Methods
Ethics statement
This study was approved by the Beijing Ditan Hospital
Ethics Committees, and informed consent was obtained
from subjects involved at the time of sample collection.
All volunteers provided written informed consent for
sample collection and subsequent analysis.
Patients and control individuals
From September 2009 to November 2009, a total of 299
confirmed cases of human infection with the novel
strain H1N1 were admitted to the intensive care unit
(ICU) of Beijing Ditan Hospital in China. We classified
the patients according to the case definition developed
by the Ministry of Health of China. The symptoms in se-
verely ill patients included: (1) sustained high fever over
3 d; (2) violent cough with purulent sputum or blood in
sputum and chest pain; (3) increased respiratory fre-
quency, dyspnea, and cyanosis; (4) altered mental status,
such as unresponsiveness, lethargy, restlessness, or sei-
zures; (5) severe vomiting or diarrhea with dehydration;
(6) signs of pneumonia in chest X-ray or computerized
tomography scan; (7) rapid increase in cardiac enzymes
including creatine kinase (CK) or creatine kinase isoen-
zyme (CK-MB), and (8) aggravation of basic illness.
Critical cases were defined when one of the following
conditions occurred: (1) respiratory failure; (2) septic
shock caused by severe infection; (3) multiple organ dys-
function syndrome, or (4) requirement of intensive care
[37]. The diagnoses were confirmed using the specific
RT-PCR protocol developed by the Center for Preven-
tion and Disease Control in Atlanta, Georgia, USA, and
recommended by WHO for Human Influenza A/H1N1/
2009 [38]. Thirteen healthy donors with no recent illness
or treatment for a chronic medical condition and diag-
nosed as negative to influenza A/H1N1 using the spe-
cific RT-PCR protocol were included as control group.
RNA isolation and quality control
Blood samples were collected in EDTA-treated tubes as
soon as the patients were admitted to the ICU. PBMCs
were isolated by standard Ficoll density gradient centri-
fugation and stored in RNAlater (Ambion) at −80°C be-
fore RNA isolation.
Total RNA was isolated using the mirVana miRNA
PARIS kit (Ambion), according to the protocol of the
manufacturer. RNA concentration and RNA integrity
were determined by capillary electrophoresis on an
Agilent 2100 Bioanalyzer (Agilent Technologies); only
the samples with RNA integrity number > 7 were used.
RNA samples were stored at −80°C until further
processing.
MiRNA expression profiling
The Agilent human miRNA microarrays (version 3.0,
based on Sanger miRBase version 13.0) [39] were used
to compare the expression profiles of critically ill pa-
tients (n = 5) and healthy controls (n = 3). The samples
used for miRNA expression profiling were randomly se-
lected from the two groups. Total RNA (100 ng) from
each sample was used as inputs for labeling via Cy3 in-
corporation. After hybridization and washing, micro-
array slides were scanned with Aligent Microarray
Scanner (Agilent, Santa Clara, CA, USA). Scans were
performed at 5 μm resolution and dye channel was set
to green (PMT100, PMT5). Labeling and hybridization
were performed at the Shanghai Biochip Company,
according to the protocols in the Agilent miRNA micro-
array system. Microarray images were analyzed with Fea-
ture Extraction Software (Agilent, Santa Clara, CA,
USA). The signal after background subtraction was
exported directly into the GeneSpring GX10 software
(Agilent Technologies, Santa Clara, CA) for quantile
normalization. The mean normalized signal from bio-
logical replicates was used for comparative expression
analysis. For the filtering step, the features (miRNA)
whose percentage of detection is 100%, under at least
one experimental condition, are retained for further ana-
lysis. Significance analysis of Microarrays [40] software
was used to determine differentially expressed miRNAs
between patient and control groups. Gene Cluster 3.0
[41] and Java TreeView software [42] were used to
Song et al. BMC Infectious Diseases 2013, 13:257 Page 3 of 15
http://www.biomedcentral.com/1471-2334/13/257
perform differentially expressd miRNA hierarchical clus-
ter analysis and visualization.
Microarray data submission
The microarray data submission for human arrays is
MIAME compliant. The raw and normalized microRNA
data have been deposited in NCBI’s Gene Expression
Omnibus (GEO) database [43] and are accessible
through GEO Series accession number GSE24956.
QRT-PCR
QRT-PCR of microRNAs was performed using Taqman
miRNA assays (Applied Biosystems, Foster City, California),
according to the instructions of the manufacturer, with the
7500 real-time PCR system (Applied Biosystems, Foster
City). The assays were performed for nine miRNAs (has-
miR-146b-5p, has-miR-148a, has-miR-150, has-miR-31,
has-miR-155, has-miR-29a, has-miR-29b, has-miR-342-5p,
and has-miR-886-3p) in larger sample sets obtained from
PBMCs of eleven critically ill patients with H1N1 infection
and thirteen healthy controls. The expression level of the
small nuclear RNU44 (RNA, U44 small nuclear) was used
as the normalization control. All assays were performed in
quadruplicate. Relative expression levels were calculated
using the 2-ΔΔCt method. Data quantification was calculated
via t-test between the patient and control groups using the
RealTime StatMiner® Software (Integromics, Spain). Two-
tailed P values ≤ 0.05 were considered statistically signifi-
cant for differences.
QRT-PCR of mRNAs was measured using an ABI
Prism 7500 (Applied Biosystems, USA) and SYBR® Pre-
mix Ex Taq™ II (Takara, Japan) according to the instruc-
tions of the manufacturer. A total of 0.5 μg of RNA
from each sample was used to generate cDNA as tem-
plates by RT with the PrimeScript RT reagent kit
(Takara, Japan). Primer pairs used for real-time PCR
were shown in Table 1. The results of the qRT-PCR were
normalized to β-actin expression. All assays were
performed in triplicate. Relative expression levels were
calculated using the 2-ΔΔCt method. Data quantification
was calculated via t-test between the patient and control
groups using the RealTime StatMiner® Software. Two-
tailed P values ≤ 0.05 were considered statistically
significant.
Receiver operating characteristic (ROC) analysis
ROC curves were established to evaluate the diagnostic
value of differentially expressed miRNAs for differentiat-
ing between critically ill patients and controls using
Graphpad Prism software (California, USA). QRT-PCR
data of the nine differentially expressed microRNAs
were used for analysis. A P value of less than 0.05 was
considered statistically significant. The ROC analysis tool
was used to determine the sensitivity and specificity of
each possible cut-off score. The cut-off score yielding
the highest sum of specificity and sensitivity was used as
optimal cut-off score.
MiRNA target prediction
Different algorithms were used for miRNA target predic-
tion, including miRanda [44], TargetScan 5.1 [45],
miRDB [46], RNA22 [47], PICTAR5 [48] and miRwalk
[49]. Only miRNA target genes identified by at least
three of these algorithms were considered.
Thus far, a few parts of important miRNA target genes
were validated in numerous studies. However, most
miRNA target genes were still not validated by experi-
ments. We obtained the validated target gene set of
these differentially expressed miRNAs from miRwalk
database.
Protein-protein interaction
In our study, we used the protein-protein interactions
from the STRING database [50], which integrates and
weighs information from numerous sources, including
conserved neighborhood, gene fusions, phylogenetic co-
occurrence, co-expression, database imports, large-scale
experiments, and literature co-occurrence [51]. The
scores higher than 0.7 will be considered as high confi-
dence [51], thus, we used the interactions with com-
bined scores higher than 0.7 for further analysis.
Enrichment analysis and network construction
DAVID [52], a functional annotation tool, was used to
analyze the enriched KEGG [53] and REACTOME [54]
pathways with default settings. The integrative network
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of miRNA-mediated host-influenza virus protein interac-
tions was drawn using Cytoscape [55].
Results
Demographic and laboratory findings of the patients
Eleven critically ill patients with no underlying diseases
were included in the study. All patients were presented
with influenza-like syndrome and met the diagnostic cri-
teria of critical case. Their mean ± SD age was 30.91 ±
8.1 years; eight patients were male and three were fe-
male. The levels of body mass index (BMI) were all
greater than 25 kg/m2. Four of the patients were cured
with noninvasive ventilation, and tracheal intubation
was performed in the other seven patients. The CT scan
showed that the pulmonary lesions of all patients rapidly
progressed. The Mean ± SD white blood cells were 6.31
± 3.66 mm3. The laboratory findings of the patients at
the time of sample collection are summarized in detail
in Table 2.
Significantly differentially expressed miRNAs differentiate
H1N1 critically ill patients from healthy control samples
We performed a series of microarray profiling of cellular
miRNAs in PBMCs from critically ill patients infected
with H1N1 influenza virus and healthy controls to iden-
tify systematic differences in miRNA expression patterns
during influenza virus infection. Forty-one human
miRNAs were significantly differentially expressed be-
tween H1N1 critically ill patients and healthy controls,
with false discovery rate lower than 0.05 and fold change
higher than 1.5 (Figure 1). The cluster analyses revealed
complete separation of the patient and control groups
based on the expression profiles of the differentially
expressed miRNAs (Figure 2).
QRT-PCR validation of differentially expressed miRNAs
and ROC analysis
The microarray data were validated by performing, qRT-
PCR for nine miRNAs, including hsa-miR-146b-5p, hsa-
miR-148a, hsa-miR-150, hsa-miR-31, hsa-miR-155, hsa-
miR-29a, hsa-miR-29b, hsa-miR-342-5p, and hsa-miR
-886-3p. We also considered hsa-miR-148a, which has
an obvious fold change, but filtered by statistics test, and
was proven highly important in previous studies. Subse-
quently, we used scatter plot to represent the relative ex-
pression levels of these nine miRNAs (Figure 3). The
qRT-PCR results were in accordance with the miRNA
microarray results. The expression of hsa-miR-150, hsa-
miR-31, hsa-miR-155, hsa-miR-29a, hsa-miR-29b, hsa-
miR-342-5p, and hsa-miR-146b-5p were present in lower
abundance, whereas hsa-miR-148a and hsa-miR-886-3p
were present in higher abundance in PBMCs from critic-
ally ill patients infected with H1N1 influenza virus than
that from healthy controls. This result indicates a posi-
tive correlation between the quantities of transcripts
measured by both microarray and qRT-PCR assay
(Figure 4).
ROC curve analyses revealed that miR-31, miR-29a
and miR-148a were valuable biomarkers for differentiat-
ing critically ill patients from controls: miR-31 yielded
Table 2 Laboratory findings on collection day
Variable Value
Days from in accident to in hospital
Mean±SD—d 5.19 ± 1.94
Leukocyte count
Mean count—per mm3 6.31 ± 3.66
Lymphocyte count
Mean count—per mm3 1.57 ± 3.10
Creatine kinase
Mean±SD—U/liter 871.3 ± 1254.02
>200 U/liter — no./total no. (%) 6/11(54.5)
Creatine kinase MB fraction
Mean±SD—U/liter [total no.] 35.4 ± 18.16 [10]
>25 U/liter—no./total no. (%) 8/10 (80.0)
Lactate dehydrogenase—U/liter
Mean±SD—U/liter 611.12 ± 368.81
C-reactive protein >10 mg/liter — no./total no. (%)
Mean±SD—U/liter 133.07 ± 56.47
Hydroxybutyrate dehydrogenase
Mean±SD—U/liter 607.91 ± 331.77
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an AUC (the areas under the ROC curve) of 0.9510
(95% CI: 0.8734–1.029; P = 0.0001884) with 81.82% sen-
sitivity and 92.31% specificity in discriminating critically
ill patients; miR-29a yielded AUC of 0.8951 (95% CI:
0.7412–1.049 P = 0.0001070) with 90.91% sensitivity and
92.31% specificity in discriminating critically ill patients,
and miR-148a yielded AUC of 0.8811 (95% CI: 0.7360–
1.026 P = 0.001601) with 72.73% sensitivity and 100%
specificity in discriminating critically ill patients(Fig-
ure 5). However, miR-146b-5p could not discrimiate crit-
ically ill patients effectively due to the P value of ROC
analysis was higher than 0.5(Figure 5). The result was
consistent with the qRT-PCR result (Figure 3). The ex-
pression level of miR-146b-5p was only slightly de-
creased in critically ill patients compared to controls
with no significant difference (P > 0.05).
MiRNA target prediction and qRT-PCR validation
Numerous studies showed that miRNAs can influence
gene expression by causing translational repression or
mRNA degradation. This dysregulation can alter several
downstream pathways and manifest effects. Therefore,
miRNA gene target predictions from miRanda,
Targetscan, miRDB, RNA22, PICTAR5, and miRwalk
[44,45,47-49,56] were performed in our study. A total of
12,117 targets with 55,838 interactions were predicted.
Interactions between proteins provide a basis for most
biological processes in an organism. The topological
analysis can help obtain important information in the
network formed by interacting proteins. Thus, in this
study, we used the protein-protein interaction data from
the STRING database [50] to construct the network of
the target genes of the differentially expressed miRNAs
to identify several ‘hub’ nodes (the high connected pro-
teins), which have an important function in influenza
virus infection. This study will help in the understanding
of the potential functions of the differentially expressed
miRNAs.
QRT-PCR was performed for these ‘hub’ nodes
expressed in the PBMCs from H1N1 patients (n = 11)
and normal controls (n = 13), including tumor protein
p53 (TP53, degree: 553), mitogen-activated protein kin-
ase 14 (MAPK14, degree: 201), Janus kinase 2 (JAK2, de-
gree: 197), caspase 3 apoptosis-related cysteine peptidase
(CASP3, degree: 158), interleukin 10 (IL-10, degree:
112), transforming growth factor beta receptor 1
(TGFBR1, degree: 67), and myxovirus resistance 1
(MX1, degree: 32). We also used scatter plot to repre-
sent the relative expression levels of these seven mRNAs
(Figure 6). The expression levels of JAK2, CASP3, IL-10,
and MX1 significantly increased, whereas TP53 and
TGFBR1 significantly decreased in PBMCs from critic-
ally ill patients infected with H1N1 influenza virus than
that from healthy controls. Only a slight increase in the
MAPK14 expression level was observed in PBMCs from
critically ill patients with no significant difference.
Integrative analysis of influenza virus-related miRNA-
mRNA regulatory network
Like all viruses, influenza virus relies on the cellular ma-
chinery of the host to support their life cycle. Tokiko
Watanabe et al. [57] summarized 1,449 cellular genes
identified to date as important for influenza virus repli-
cation from several RNAi-based genome-wide screening
experiments. Identifying the host functions co-opted for
viral replication is of interest for the understanding of
Figure 1 Differentially expressed microRNAs between patients and control groups. The diagram shows the fold changes of miRNAs that
passed the filtering criteria using SAM software between the two groups in the analysis. FDR lower than 0.05 and fold change higher than 1.5
was set as standard. Up-regulated and down-regulated miRNAs are indicated by bars above and below the horizontal axis respectively. The q-
values are indicated above the bars.
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the mechanisms of the virus life cycle and to find valu-
able targets of differentially expressed miRNAs in our
study. We obtained the data of virus-host interactions
from previous studies [6,7], which can provide more in-
sights into the molecular mechanism of diseases at sys-
tematic level.
Functional enrichment analysis (P < 0.05) performed
to these cellular genes revealed various over-represented
pathways, including the MAPK signaling pathway, Toll-
like receptor signaling pathway, B cell receptor signaling
pathway, T cell receptor signaling pathway, Wnt signal-
ing pathway, chemokine signaling pathway, apoptosis,
Jak-STAT signaling pathway, epidermal growth factor re-
ceptor (EGFR) signal pathway, mTOR signal pathway,
and TGF-beta signaling pathway, which are critical cel-
lular pathways related to virus infection.
Among these cellular genes, we summarized the inter-
actions between nodes in these enriched KEGG path-
ways to construct a combined pathway network.
Topological analysis was then performed to determine
which nodes can be major regulators and receivers. A
major regulator is defined as a node that exerts control
over at least five other nodes, whereas a major receiver
is influenced by a minimum of five nodes. The nodes
with a degree of more than 3 in the combined network
were selected to form a subnetwork for further analysis,
in which we added the data of miRNAs who have targets
validated by previous studies or predicted by a large
number of algorithms on the major regulators and re-
ceivers. With the additional data of virus-host interac-
tions, we were able to construct Figure 7.
Our data suggest that miRNA dysregulation in the
PBMCs of H1N1 critically ill patients can regulate a
number of key genes in the major signaling pathways as-
sociated with influenza virus infection.
Discussion
MiRNAs have been reported to participate in regulating
cross-talk between the host and the pathogen in viral in-
fections, which have a major function in viral pathogen-
esis [12-14]. Cellular miRNAs can also be involved in
regulating the molecular pathways of innate and adap-
tive immune responses, and can act as an antiviral
defense mechanism or even inhibit virus replication dir-
ectly [58,59]. Cellular miRNAs can be used by viruses
for their own advantage. For example, the hepatitis C
virus (HCV) replication is dependent on cellular miR-
122 expression. The HCV RNA genome contains two
miR-122 binding sites in its 5′UTR, which are required
to activate viral genomic RNA replication. Increased
miR-122 expression can result in regulating anti-
apoptotic genes and enhancing viral replication to pro-
mote cell proliferation [60-62].
In our study, we used PBMC cell samples from critic-
ally ill patients with H1N1 influenza and identified nu-
merous differentially expressed miRNAs (Figure 1).
QRT-PCR assay and ROC curve analyses revealed that
miR-31, miR-29a and miR-148a all had significant poten-
tial diagnostic value for critically ill patients infected
with H1N1 influenza virus, which yielded AUC of
0.9510, 0.8951 and 0.8811, respectively (Figures 3 and 5).
Some of these differentially expressed miRNAs via in
silico analysis targeted mRNAs of several key genes, in-
cluding TP53, CASP3, JAK2, IL-10, MX1, TGFBR1, and
Figure 2 A hierarchical clustering tree map comparing
expression of miRNAs between patient (HE) and healthy
control (HC) samples. The clustering was performed on
standardized log2 signals for the differentially expressed miRNAs,
using Pearson correlation and average linkage clustering method.
Green or red bars denote that the level of specific microRNA was
decreased or increased in samples.
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MAPK14. These changes affect numerous other genes
and regulators of metabolism and signaling pathways.
These subset gene changes are crucial to H1N1 infection
and are responsible for disease progression.
MiR-29a and miR-29b were reported to be
downregulated in lung tissues from mice infected with
reconstructed 1918 or a nonlethal seasonal influenza
virus, Tx/91 [17]. This was consistent with our result.
Both miR-29a and miR-29b could repress IFN-gamma
production by direct targeting of both T-box transcription
factor T-bet and Eomesodermin (Eomes), two transcrip-
tion factors known to induce IFN-gamma production
[63]. Therefore, the downregulated miR-29 may regulate
the T helper 1 (Th1) cell differentiation to secrete more
IFN-gamma and mediate elimination of intracellular path-
ogens, but dysregulated T cell responses may also contrib-
ute to pathologic inflammation.
E. K. Loveday et al. demonstrated that miR-29a, miR-
29c and let-7g were down-regulated in human A549
cells infected with swine-origin influenza pandemic
H1N1 [21]. This was consistent with our result. Let-7g
could inhibit lectin-like oxidized low-density lipoprotein
receptor-1 expression and inhibits apoptosis, by which
may suggest increased cell apoptosis [64]. Moreover, let-
7g could inhibit the expression of IL-13, a key inducer of
airway inflammation secreted by TH2 lymphocytes and
other cells [65,66]. Therefore, down-regulation of miR-
29a, miR-29c and let-7g may contribute to the uncon-
trolled inflammation by allowing up-regulation of pro-
inflammation genes.
The critically ill patients in this study all had no
underlying diseases including type 2 diabetes, immuno-
deficiency or cardiopulmonary diseases, but they had
comorbidities like pneumonia or acute respiratory
Figure 3 qRT- PCR analysis of 9 miRNAs expression in the PBMCs from patients with H1N1 (n = 11) and normal controls (n = 13). qRT-
PCR analysis of 9 miRNAs expression in the PBMCs from H1N1 critically ill patients (n = 11;8 male 3 female; age 31 ± 8 y [mean±SD]) and healthy
controls (n = 13; 9 male 4 female; age 29 ± 5 y [mean±SD]). The relative expression levels were normalized to the expression of RNU44. HE: H1N1
critically ill patients HC: healthy controls. * P < 0.05; **P < 0.01; ***P < 0.005.
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distress syndrome (ARDS), which may lead to disease
progression. We collected samples as soon as patients were
admitted to ICU with confirmed influenza A H1N1 infec-
tion, when they were very severe and immediately treated
with anti-infective therapy and so on. Interestingly, we found
all the critically ill patients in our study were overweight
(BMI > 25 kg/m2). Many reports support the view that obes-
ity is associated with higher risks of ICU admission and
death in patients with influenza A (H1N1) infection [67-69].
Other findings suggest that obese patients with severe infec-
tion were more likely to develop pneumonitis compared to
non-obese patients [70-72]. Infection with influenza virus in
diet-induced obese mice was shown to dysregulate immune
response, expecially impair the T cell memory response, and
lead to increased morbidity and mortality from viral infec-
tion [73-75]. A recent study reported that the expression of
miR-146b-5p was decreased in monocytes during obesity
[76]. MiR-146b-5p acts as an inhibitor of NF-κB-mediated
inflammation and is necessary for the anti-inflammatory ac-
tion of high levels of globular adiponectin. Another group
found that let-7g was downregulated in the fetal muscle
of diet-induced obese ovine compared to control. The
downregulation of let-7g may enhance intramuscular
adipogenesis during fetal muscle development in the setting
of maternal obesity [77]. Taken together, our findings suggest
the downregulation of miR-146b-5p and let-7g were import-
ant in further understanding the molecular mechanisms im-
plicated in obese patients susceptive to severe infection of
H1N1 influenza virus.
Schmidt et al. [78] found that miR-146b-5p, miR-150,
miR-342-3p and let-7g were downregulated in peripheral
blood leukocytes during acute lipopolysaccharide (LPS)
induced inflammation, which was similar to our result.
Several genes encoding proteins involved in NF-κB and
MAPK signaling as well as cytokine pathways and other
inflammation pathways were predicted targets of these
LPS-responsive miRNAs. These miRNAs may play an
important role in controlling the level of inflammatory
response. A predisposition for pneumococcal infections
after H1N1 influenza virus infection has been reported
[79]. Streptococcus pneumonia co-infection is correlated
with the morbidity and the mortality of H1N1 pandemic
influenza [80]. Therefore, this result is reasonable be-
cause most of our patients had pulmonary infections.
The p38 MAPK are a class of MAPKs.kinases. The p38
MAPK pathway is strongly activated by stress, but also
has important functions in the immune response and in
regulating cell survival and differentiation, which allows
cells to interpret a wide range of external signals and re-
spond appropriately by generating a large number of dif-
ferent biological effects [81]. Studies have shown that
influenza virus infection activates MAPK family members
in mammals, and the expression of RANTES, IL-8, and
tumor necrosis factor-alpha were controlled by p38 activa-
tion [82]. P38 MAPK is a determinant of virus infection,
which depends on MyD88 expression and Toll-like recep-
tor 4 (TLR4) ligation, and the inhibition of p38 MAPK sig-
naling significantly inhibits virus replication [83].
However, in our study, MAPK14 mRNA expression in
critically ill patients had no significant change compared
with healthy controls, indicating that the response and the
regulation of key gene expression for survival in H1N1
critically ill patients is highly complex. P38 MAPKs
(MAPK11, MAPK13, and MAPK14) were found to be
regulated by miR-769-5p, miR-146b-5p, let-7g, miR-30b,
miR-31, miR-361-3p, and miR-362-3p (Figure 7), which
were all down expressed in H1N1 critically ill patients.
Thus, increasing the expression of miRNAs targeting p38
MAPKs in H1N1 critically ill patients can help inhibit
virus replication. These miRNAs can have an antiviral
function during influenza virus infection.
We found that EGFR was regulated by miR-342, miR-
155, miR-30b, miR-210, miR-192, let-7g, and miR-146b
-5p, which were all down expressed in H1N1 critically ill
Figure 4 Comparison of miRNA expression levels obtained by
miRNA microarray and Taqman qRT-PCR analysis.
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patients. EGFR can promote the uptake of influenza viruses
into host cells by forming a lipid raft-based signaling plat-
form with sialic acids and other receptor tyrosine kinases
(RTKs) [84]. These downregulated miRNAs can upregulate
EGFR expression, resulting in easier virus replication and
propagation at the early stage of infection. This result is
additionally supported by that of a recent siRNA screening
study, which identified the fibroblast growth factor recep-
tors 1, 2, and 4 as RTKs involved in the early stages of viral
infection [6]. The downregulation of this kind of miRNAs
helps to regulate the host antiviral response or to benefit
the virus by allowing virus replication.
Apoptosis is a hallmark event observed in infection with
numerous viral pathogens, including influenza A virus
[85]. Sequential activation of caspases can have a central
function in the execution phase of cell apoptosis. CASP3
is a major virus-induced apoptosis effector, which can be
activated by CASP9 (Figure 7). A previous study showed
that the presence of inhibitor that blocks CASP3 or
knock-down of CASP3 by siRNAs can significantly impair
influenza virus propagation, proving the importance of
CASP3 activation for efficient influenza virus replication
during the onset of apoptosis [85]. In our study, CASP3
was significantly upregulated by qRT-PCR analysis (Fig-
ure 6) and targeted by the downregulated miRNAs: miR-
342-3p, miR-29b, miR-29c, miR-29a, let-7g and miR-30b,
which can be expected to develop miRNA-based thera-
peutics for influenza disease.
Figure 5 ROC curve analysis using differentially expressed miRNAs for discriminating critically ill patients.
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Transforming growth factor beta (TGF-beta) is a family
of proteins secreted by virtually all cells. TGF-beta levels
increase during viral infection, and significant TGF-beta
levels activated by influenza virus exist to induce cell apop-
tosis [86]. In our study, TGF-beta receptor 1 (TGFBR1)
was found to be downregulated (Figure 6). TP53 is a well-
known tumor suppressor that responds to diverse cellular
stresses to regulate target genes that induce cell cycle ar-
rest, apoptosis, and senescence. TP53 was also found to be
downregulated. A response mechanism of host cell pos-
sibly exists to remit apoptosis induced by influenza virus.
Moreover, TGFBR1 and TP53 were both predicted to be
regulated by high-expressed miR-148a.
We found that miR-148a was significantly upregulated
compared with the control samples by qRT-PCR assay, in-
dicating that miR-148a has an important function in influ-
enza virus infection. MiR-148a has been associated with
different types of cancer [87,88] and autoimmune diseases,
such as multiple sclerosis [23], asthma [89] and systemic
lupus erythematosus [90]. A recent study has demon-
strated that miR-148a expression is also upregulated in
DCs on maturation and activation induced by TLR3,
TLR4, and TLR9 agonists, which, in turn, inhibit the
upregulation of MHC class II expression, the production
of cytokines including IL-12, IL-6, TNF-alpha, and IFN-
beta, and antigen presentation of DCs by directly targeting
Calcium/calmodulin-dependent protein kinase II [91].
Their result indicates that miR-148a is a negative regulator
of the innate response and antigen presenting capacity of
DCs. The upregulated miR-148a in PBMCs of H1N1 crit-
ically ill patients may contribute to the regulation of in-
nate and adaptive immune responses.
Our miRNA microarray and RT-PCR analysis revealed
that miR-31 was significantly down-expressed in PBMCs
of H1N1 critically ill patients. MiR-31 can negatively
regulate FOXP3 expression by binding directly to its
Figure 6 qRT- PCR analysis of 6 mRNAs expressed in the PBMCs from patients with H1N1 (n = 11) and normal controls (n = 13). The
relative expression levels were normalized to the expression of β-actin. HE: H1N1 critically ill patients HC: healthy controls. * P < 0.05; **P < 0.01;
***P < 0.005.
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potential target site in the 3′UTR of FOXP3 mRNA
[92]. Foxp3+ T regulatory (Treg) cells have an important
function in inducing and maintaining immunological
tolerance [93]. FoxP3+ Treg cell was significantly in-
creased among H1N1- infected patients compared with
normal controls by flow cytometry analysis [79,94]. The
inverse correlation between miR-31 expression and Treg
cell number in the PBMC of H1N1 critically ill patients
can be explained by the negative regulation of FOXP3
expression.
Mx1 protein was proven highly important for long-
term protection against influenza virus infection [95-97].
Recently, Cilloniz et al. found that Mx1+/+ mice can
generate a protective antiviral response by controlling
the expression of key modulator molecules associated
with influenza virus lethality [98]. In our study, we found
that Mx1 mRNA was significantly upregulated in H1N1
critically ill patients by qRT-PCR assay. No validated
miRNA targeting Mx1 has been reported; thus, our
miRNA target prediction result indicated that Mx1 can
be negatively regulated by miR-342-3p and miR-210,
which were both down expressed in H1N1 critically ill
patients. Therefore, increasing the Mx1 expression by
inhibiting these two miRNAs can enhance protection
against influenza virus infection.
Adopting a global perspective is important when investi-
gating infections. A systems biology approach to infectious
disease research, which models various interacting com-
ponent networks, will permit greater understanding of the
molecular mechanism and the interplay between the host
and pathogen. In our study, with integrated various infor-
mation (miRNA targets, miRNA-mediated pathways, virus
proteins, et al.), we obtained a combined network of core
information related to H1N1 infection. A better under-
standing of the network of genes and cellular pathways
regulated by these miRNAs will undoubtedly enable us to
characterize the host antiviral mechanism comprehen-
sively and to find new targets for developing antiviral
compounds.
Although the results of our study can lead to under-
standing further the functions of miRNAs in influenza
virus infection, additional experiments, such as miRNA
Figure 7 Influenza virus-related regulatory network. KEGG pathway analysis was performed on cellular genes identified as important for
influenza virus replication. The interactions between nodes in these enriched KEGG pathways were summarized to construct a combined
pathway network. The degree level of each gene is represented by the size of the node. The color gradient of the green nodes, from light to
dark, shows the value of in-degree of the receivers, from low to high; meanwhile, the color gradient of the red nodes, from light to dark, shows
the value of out-degree of the regulators, from low to high. The nodes with degree more the 3 in the combined network were showed in the
core sub-network. MiRNAs were located near their targets, and so were the virus proteins which were represented by red fonts.
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target validation, in vivo western blot, and pull-down as-
says during infection and larger cohort of patients clin-
ical investigation are still needed to validate and to
refine our observations.
Conclusions
We identified the systematic differences in miRNA ex-
pression patterns between PBMCs from H1N1 critically ill
patients and healthy controls. Using RT-PCR analysis, we
verified nine important differentially expressed miRNAs
and validated seven core genes. ROC curve analyses re-
vealed that miR-31, miR-29a and miR-148a all had signifi-
cant potential diagnostic value for critically ill patients
infected with H1N1 influenza virus, which yielded AUC of
0.9510, 0.8951 and 0.8811, respectively. In addition, we
found that a number of genes and signaling pathways that
are important to influenza virus infection are likely to
be regulated, at least partly, by miRNAs. Finally, we
constructed an influenza virus-related miRNA-mRNA
regulatory network, which can lead to a global perspective
for investigating influenza virus infection.
Therefore, further understanding the functions of
these miRNAs in influenza virus infection will provide
new insight into the host-pathogen interactions and
pathogenesis.
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